ALS Organizations Collaborate to Advance New Therapeutic into Trials

Contact: Brian Frederick The ALS Association (202) 464-8612 bfrederick@alsa-national.org FOR IMMEDIATE RELEASE ALS Organizations Collaborate to Advance New Therapeutic into Trials First dose of potential treatment AT-1501 given to humans by Anelixis Therapeutics to determine safety and tolerability Boston, MA (November 28, 2018) — Several ALS organizations announced on Wednesday that the first participant was successfully … Continue reading ALS Organizations Collaborate to Advance New Therapeutic into Trials